Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01035255 · ClinicalTrials.gov registry record · Phase 3
This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 8,442
- Enrollment target
NCT01035255: Clinical Trial Phase 3 study, sponsored by Novartis Pharmaceuticals.
NCT01035255 is a Phase 3 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 8,442 participants, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (995% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01035255, a Phase 3 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 8,442 participants
- Enrollment target
Study Summary
The study will evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure (NYHA Class II - IV and EF =\< 35%).
Primary Outcome
Number of participants that had first occurrence of the composite endpoint, which is defined as either CV death or HF hospitalization due to HF.
Interventions
- DRUG LCZ696 200 mg BID
- DRUG Enalapril 10 mg BID
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8,442 participants |
| Start Date | 2009-12 |
| Est. Completion | 2014-05 |
| Phase | Phase 3 |
Why NCT01035255 stopped before completion
NCT01035255 is an interventional study that assigns participants to a tested intervention. Its 8,442 participants enrollment target places it among the larger protocols in the corpus, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (995% higher).
The record links to 0 conditions, and to 2 interventions - of which LCZ696 200 mg BID is the first listed.
NCT01035255 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01035255 about?
NCT01035255 is a clinical study titled "This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure". The study will evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure (NYHA Class II - IV and EF =\< 35%).
What is the current status of trial NCT01035255?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 8,442 participants. The study started on 2009-12. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01035255?
The interventions under investigation include: LCZ696 200 mg BID (DRUG), Enalapril 10 mg BID (DRUG).
Who is sponsoring clinical trial NCT01035255?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01035255's enrollment target sits among peer trials
8,442 32nd of 2000 higher than 1,969 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07185828 · 8,286 participants · NA
Informing Low-acuity Emergency Department Patients of Non-emergent Resources (2)
- NCT06098079 · 8,600 participants · Phase 4
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
- NCT06058234 · 8,680 participants
Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study
- NCT06435806 · 8,200 participants · NA
Medical Illustration Design Characteristic Evaluation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia